• Genetic Signatures appoints Non-Executive Director Anne Lockwood as interim Managing Director
• Lockwood brings over 30 years' experience in finance, risk management and audit
• Appointment strengthens leadership team and positions company for strategic execution

Genetic Signatures Limited [ASX:GSS] ('GSS' or the 'Company'), a global molecular diagnostics company, has announced that its Board of Directors has appointed Non-Executive Director Anne Lockwood as interim Managing Director. The appointment is intended to strengthen the Company's leadership team at an important time and place Genetic Signatures in a position of strength, underpinned by deep financial management, capital discipline and governance expertise. Mrs Lockwood brings over 30 years' experience across finance, risk management and audit, including deep expertise in mergers and acquisitions and capital market transactions across a range of industries. She was appointed to the Board of Genetic Signatures in October 2024 and has held various senior roles, including Chief Financial and Commercial Officer of ASX-listed Integral Diagnostics Limited and Non-Executive Director at Symal Group Limited, Coventry Group Limited and Mayne Pharma Group Limited. In her role as interim Managing Director, Mrs Lockwood will work closely and collaboratively with newly appointed Chief Executive Officer, Maria Halasz, supporting execution of the Company's strategy while maintaining strong financial oversight. Mrs Lockwood will assume the role for a six-month period, after which the Board will review the Company's longer-term management arrangements.